Exploring Irisin Levels in Patients with Endometrial Atypical Hyperplasia and Carcinoma: A Comparative Analysis

Abstract

Background Endometrial atypical hyperplasia is recognized as the precursor to type I endometrial cancer. Endometrial cancer, strongly associated with disorders in glucose metabolism such as obesity and insulin resistance, is believed to be influenced by hormones secreted from adipose tissue known as adipokines. Methods In a prospective case-control study, 88 patients diagnosed with either endometrial atypical hyperplasia or endometrial cancer were enrolled. Their irisin levels in serum were compared to those of a control group. Results Irisin levels were found to be significantly higher in patients diagnosed with both endometrial atypical hyperplasia and endometrial cancer compared to the control group (p = .022). Conclusion We demonstrated that Irisin levels in patients with EAH or EC differ from those in a control group, suggesting that irisin levels are correlated with the risks of EH and EC. Larger studies are required to clarify the potential use of irisin in the diagnosis of EC.